has been cited by the following article(s):
|
[1]
|
ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
|
|
2021 |
|
|
|
|
[2]
|
ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based …
|
|
2020 |
|
|
|
|
[3]
|
ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy
|
|
2020 |
|
|
|
|
[4]
|
The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients
|
|
2018 |
|
|
|
|
[5]
|
Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
|
|
2017 |
|
|
|
|
[6]
|
Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis
|
|
2017 |
|
|
|
|
[7]
|
ERCC1 Expression as a Predictor of Resistance to Platinum-based Chemotherapy in Primary Ovarian Cancer
|
|
Anticancer …,
2014 |
|
|
|
|
[8]
|
Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression
|
|
International …,
2014 |
|
|
|
|
[9]
|
Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism of ERCC1: a meta-analysis
|
|
Biomarkers,
2014 |
|
|
|
|
[10]
|
Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced …
|
|
2013 |
|
|
|
|
[11]
|
Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population
|
|
Journal of cancer …,
2013 |
|
|
|
|
[12]
|
Excision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced …
|
|
2013 |
|
|
|
|
[1]
|
ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
Journal of Ovarian Research,
2021
DOI:10.1186/s13048-021-00831-y
|
|
|
|
|
[2]
|
The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients
BMC Medical Genetics,
2018
DOI:10.1186/s12881-018-0627-4
|
|
|
|
|
[3]
|
Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
BMC Women's Health,
2017
DOI:10.1186/s12905-017-0393-z
|
|
|
|
|
[4]
|
Genetic variants as ovarian cancer first-line treatment hallmarks: A systematic review and meta-analysis
Cancer Treatment Reviews,
2017
DOI:10.1016/j.ctrv.2017.10.001
|
|
|
|
|
[5]
|
Predicting the outcome of platinum-based chemotherapies in epithelial ovarian cancer using the 8092C/A polymorphism ofERCC1: a meta-analysis
Biomarkers,
2014
DOI:10.3109/1354750X.2014.882414
|
|
|
|
|
[6]
|
Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression
International Journal of Oncology,
2014
DOI:10.3892/ijo.2014.2311
|
|
|
|